Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

被引：0
作者：
J Bray
J Sludden
M J Griffin
M Cole
M Verrill
D Jamieson
A V Boddy
机构：
[1] Northern Institute for Cancer Research,
[2] Paul O'Gorman Building,undefined
[3] Medical School,undefined
[4] Newcastle University,undefined
[5] Northern Centre for Cancer Care,undefined
[6] Newcastle Freeman Hospital,undefined
来源：
British Journal of Cancer | 2010年 / 102卷
关键词：
breast cancer; doxorubicin; cyclophosphamide; pharmacogenetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1003 / 1009
页数：6
相关论文
共 50 条
  • [21] Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide
    Montella, L.
    Addeo, R.
    Guarrasi, R.
    Cennamo, G.
    Faiola, V.
    Capasso, E.
    Caraglia, M.
    Del Prete, S.
    EUROPEAN JOURNAL OF CANCER CARE, 2010, 19 (02) : 200 - 204
  • [22] Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients
    Chow, L. W. C.
    Biganzoli, L.
    Leo, A. D.
    Kuroi, K.
    Han, H. S.
    Patel, J.
    Huang, C. S.
    Lu, Y. S.
    Zhu, L.
    Chow, C. Y. C.
    Loo, W. T. Y.
    Gluck, S.
    Toi, M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (06) : 372 - 378
  • [23] Pharmacogenetics of response to neoadjuvant paclitaxel treatment for locally advanced breast cancer
    Perez-Ortiz, Andric C.
    Ramirez, Israel
    Cruz-Lopez, Juan C.
    Villarreal-Garza, Cynthia
    Luna-Angulo, Alexandra
    Lira-Romero, Esmeralda
    Jimenez-Chaidez, Salvador
    Diaz-Chavez, Jose
    Matus-Santos, Juan A.
    Sanchez-Chapul, Laura
    Mendoza-Lorenzo, Patricia
    Estrada-Mena, Francisco J.
    ONCOTARGET, 2017, 8 (63) : 106454 - 106467
  • [24] Toxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective cohort study
    Gadisa, Diriba Alemayehu
    Assefa, Mathewos
    Wang, Shu-Hua
    Yimer, Getnet
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (08) : 1912 - 1920
  • [25] Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer
    Hwang, Mary
    Medley, Sarah
    Shakeel, Faisal
    Vanderwerff, Brett
    Zawistowski, Matthew
    Kidwell, Kelley M.
    Hertz, Daniel L.
    SUPPORTIVE CARE IN CANCER, 2022, 30 (09) : 7355 - 7363
  • [26] Pharmacogenetics in Endocrine Therapy of Patients with Breast Cancer
    Lux, M. P.
    Brauch, H.
    Fehm, T.
    Janni, W.
    Maass, N.
    Rody, A.
    Harbeck, N.
    Niederachers, D.
    Beckmann, M. W.
    Fasching, P. A.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 (12) : 1192 - 1200
  • [27] Efficacy of reduced dose of pegfilgrastim in Japanese breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide therapy
    Mizuno, Yoshio
    Fuchikami, Hiromi
    Takeda, Naoko
    Iwai, Masaru
    Sato, Kazuhiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (01) : 12 - 17
  • [28] Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer
    Mary Hwang
    Sarah Medley
    Faisal Shakeel
    Brett Vanderwerff
    Matthew Zawistowski
    Kelley M. Kidwell
    Daniel L. Hertz
    Supportive Care in Cancer, 2022, 30 : 7355 - 7363
  • [29] Efficacy and toxicity of vinorelbine with doxorubicin/cyclophosphamide combination chemotherapy in a phase I-II study for advanced or recurrent breast cancer patients.
    Saeki T.
    Takashima S.
    Ogita M.
    Tabei T.
    Adachi I.
    Tamura K.
    Takatsuka Y.
    Kanda K.
    Breast Cancer, 2006, 13 (2) : 159 - 165
  • [30] RECOVERY OF RESPONSE TO ADRIAMYCIN AND CYCLOPHOSPHAMIDE BY LONIDAMINE IN PREVIOUSLY TREATED METASTATIC BREAST-CANCER PATIENTS
    TOMIROTTI, M
    BERNARDO, G
    EPIFANI, C
    BIASIOLI, R
    FRANCHI, R
    MENSI, F
    CARNAGHI, P
    SCHIEPPATI, G
    SCANNI, A
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1993, 3 (02) : 213 - 217
12345